Advertisement

The impact of oral anticoagulant drugs for arterial thromboembolism in patients with cancer

Published:January 20, 2022DOI:https://doi.org/10.1016/j.ejim.2022.01.028

      Highlights

      • Newly diagnosed cancer patients have a significantly increased risk of arterial thrombotic events in the 12-month period following cancer diagnosis.
      • Guidelines recommend anticoagulant venous thromboembolism treatment in cancer patients
      • There is no evidence on the role of anticoagulants in the prevention of arterial thrombosis events.
      • OAC therapy initiated for different and non-cancer-related clinical reasons in cancer patients does not appear to reduce the described higher risk of arterial thrombotic events.
      • Antithrombotic alternatives should be evaluated in this setting in the context of clinical intervention studies of adequate size and design.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Blom J.W.
        • Doggen C.J.
        • Osanto S.
        • Rosendaal F.
        Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
        JAMA. 2005; 293: 715-722https://doi.org/10.1001/jama.293.6.715
        • Navi B.B.
        • Reiner A.S.
        • Kamel H.
        • Iadecola C.
        • Okin P.M.
        • Elkind M.S.V.
        • Panageas K.S.
        • DeAngelis LM.
        Risk of Arterial Thromboembolism in Patients With Cancer.
        J Am Coll Cardiol. 2017; 70: 926-938https://doi.org/10.1016/j.jacc.2017.06.047
        • Amer M.H.
        Cancer-associated thrombosis: clinical presentation and survival.
        Cancer Manag Res. 2013; 5: 165-178https://doi.org/10.2147/CMAR.S47094
        • Wang J.
        • Kim Y.D.
        • Kim C.H.
        Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer.
        Mayo Clin Proc. 2021; 96: 592-600https://doi.org/10.1016/j.mayocp.2020.05.045
        • Navi B.B.
        • Reiner A.S.
        • Kamel H.
        • Iadecola C.
        • Okin P.M.
        • Tagawa S.T.
        • Panageas K.S.
        • DeAngelis L.M.
        Arterial thromboembolic events preceding the diagnosis of cancer in older persons.
        Blood. 2019; 133: 781-789https://doi.org/10.1182/blood-2018-06-860874
        • Grilz E.
        • Königsbrügge O.
        • Posch F.
        • Schmidinger M.
        • Pirker R.
        • Lang I.M.
        • Pabinger I.
        • Ay C.
        Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.
        Haematologica. 2018; 103: 1549-1556https://doi.org/10.3324/haematol.2018.192419
        • Gervaso L.
        • Dave H.
        • Khorana A.A.
        Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review.
        JACC CardioOncol. 2021; 3: 173-190https://doi.org/10.1016/j.jaccao.2021.03.001
        • Statistics Denmark
        (DAFFODIL database).
        Statistics Denmark, Copenhagen, Denmark2019 (Last Accessed: November, 25, http://www.dst.dk/en)
        • Dahm A.E.A.
        Cancer and Thrombosis: New Treatments, New Challenges.
        Med Sci (Basel). 2021 Jun 3; 9: 41https://doi.org/10.3390/medsci9020041